Considerations Following Locoregional Therapy in HCC
Considerations Following Locoregional Therapy in HCC
May 2015
- 64-year old obese female presented with fatigue and unexplained weight loss
- History of nonalcoholic fatty liver disease (NAFLD), then nonalcoholic steatohepatitis (NASH)
- Lab results: AFP= 1,500 IU/ml
- ECOG=1; Child-Pugh A
- CT revealed 1 large liver mass, right side of liver close to a major blood vessel
- No extrahepatic disease
- Liver-directed therapy with DEB-TACE was performed
- Patient reported abdominal pain following DEB-TACE and required analgesics; low-grade fever
- Patient had a complete response
- AFP= 200 IU/ml at follow up
February 2017
- Follow-up imaging showed progression and evidence of bone metastases
- Therapy was initiated with sorafenib at 400 mg BID
- Follow-up testing showed liver decompensation
Related Videos
Related Content
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024Article
In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024Article
In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
